MiYOSMART iQ spectacle lenses to slow myopia in children
Official title: Prospective, Interventional, Single-center Study to Evaluate the Influence of MiYOSMART iQ Spectacle Lenses With DIMS and Triple Enhanced Design Technology on Refraction Dynamics, Biometric Parameters, Peripheral Refraction and Contrast Sensitivity in Children With Myopia
Run by Hoya Lens Rus LLC · NCT07387159 · Data updated 2026-11-12
This study will test whether MiYOSMART iQ DIMS spectacle lenses slow myopia progression in 8–11-year-old children.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 8 Years to 11 Years |
| Sex | All |
| Enrollment | 70 (estimated) |
| Sponsor | Hoya Lens Rus LLC Industry-sponsored |
| Locations | 1 site (Moscow) |
| Status | Recruiting |
| Started | February 4, 2026 |
| Main results expected | December 31, 2026 |
| Study ends | February 28, 2027 |
| Registry record updated | February 6, 2026 |
| Trial ID | NCT07387159 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Children aged 8–11 years with cycloplegic myopia of −0.5 to −6.0 D, normal binocular vision, and no prior myopia-control treatment are ideal candidates.
✕Probably not a fit
Children outside the age or prescription range, or those with poor corrected visual acuity, anisometropia >2.0 D, strabismus, or prior refractive/intraocular surgery are unlikely to benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This prospective, single-center study will enroll 35 children aged 8–11 years with cycloplegic spherical equivalent between −0.5 and −6.0 D who will be prescribed MiYOSMART iQ spectacle lenses and followed for six months. Changes in spherical equivalent refraction and axial length will be compared to a historical control group (n=35) using ANCOVA. Secondary outcomes include measurements of peripheral refraction and contrast sensitivity at the first prescription, and safety data will be collected throughout. The trial is designed to characterize DIMS/TED optical effects in a Russian pediatric population and in a real-world clinical setting.
Why it matters
Potential benefit: If successful, these lenses could slow myopia progression in young children and reduce their long-term risk of sight-threatening eye disease.
How similar studies have gone: Previous trials, mainly in Asian populations, have shown MiYOSMART/DIMS lenses can slow myopia progression, but evidence in Caucasian cohorts and short-term real-world settings is more limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 8-11 years (inclusive) * Myopia: spherical equivalent -0.5 to -6.0 D under cycloplegia * No previous myopia control treatment * Orthophoria, presence of binocular vision Exclusion Criteria: * Corrected visual acuity \< 0.8 (decimal) * Anisometropia \> 2.0 D * Strabismus history or presence * Previous refractive or intraocular surgery
Where it's running
-
Helmholtz National Medical Research Center of Eye Diseases
Moscow, Russia Recruiting
Study contacts
- Study coordinator: Elena Tarutta, MD, PhD
- Email: Otdel_ref_bin2@igb.ru
- Phone: +7(916)121-19-53
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Using DIMS Glasses to See if Myopia Progression Slows in Kids
This observational study tests whether wearing DIMS glasses in children and teens with myopia can slow progression, considering factors like outdoor time and family history.
-
New-generation myopia-control lenses versus an earlier lens for children 6–14
This test tries whether a new myopia-control lens (MCL1) slows eye growth more than a previous-generation lens (MCL2) in children aged 6 to 14.
-
Low-dose atropine eye drops to slow myopia in children
This tests whether nightly 0.025% atropine eye drops slow worsening of myopia in children aged 5 to 10 compared with placebo.
-
Where children look through their glasses
This trial tests how children ages 7–14 look through a new spectacle lens design to see which parts of the lens they use during different tasks.
-
Children wearing spectacle lenses: mobility during everyday activities
This test checks whether myopia-control spectacle lenses change how children aged 6–12 move and perform everyday mobility tasks compared with regular single-vision glasses.
-
Testing low-dose atropine eye drops to slow down myopia in children
This study is testing if low-dose atropine eye drops can help slow down worsening eyesight in children aged 6 to 12 who have myopia.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.